Table of Contents
International Scholarly Research Notices
Volume 2014, Article ID 639489, 6 pages
http://dx.doi.org/10.1155/2014/639489
Clinical Study

Adding of Sitagliptin on Insulin Therapy Effectively and Safely Reduces a Hemoglobin A1c Level and Glucose Fluctuation in Japanese Patients with Type 2 Diabetes

1Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume 830-0011, Japan
2Municipal Yame General Hospital, Yame 834-0034, Japan
3Kouhoukai Takagi Hospital, Okawa 831-0016, Japan
4Inada Clinic, Kurume 830-0039, Japan
5Shimada Hospital, Ogori 838-0141, Japan
6Tenjinkai Koga Hospital 21, Kurume 839-0801, Japan
7Saint Mary Hospital, Kurume 830-8543, Japan
8Tenjinkai Shin-Koga Hospital, Kurume 830-8577, Japan

Received 10 March 2014; Accepted 5 June 2014; Published 3 August 2014

Academic Editor: Qi Zhang

Copyright © 2014 Yuji Tajiri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Hermansen, M. Davies, T. Derezinski, G. Martinez Ravn, P. Clauson, and P. Home, “A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people wih type 2 diabetes,” Diabetes Care, vol. 29, pp. 1269–1274, 2006. View at Google Scholar · View at Scopus
  2. Y. Iwamoto, N. Tajima, T. Kadowaki et al., “Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial,” Diabetes, Obesity and Metabolism, vol. 12, no. 7, pp. 613–622, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Tajiri, M. Tsuruta, T. Ohki et al., “Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan,” Endocrine Journal, vol. 59, no. 3, pp. 197–204, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Vilsbøll, J. Rosenstock, H. Yki-Järvinen et al., “Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 12, no. 2, pp. 167–177, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Hollander, K. Raslova, T. V. SkjØth, J. Råstam, and J. F. Liutkus, “Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial,” Diabetes, Obesity and Metabolism, vol. 13, no. 3, pp. 268–275, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. E. S. Hong, A. R. Khang, J. W. Yoon et al., “Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study,” Diabetes, Obesity and Metabolism, vol. 14, no. 9, pp. 795–802, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Takahara, T. Shiraiwa, H. Kaneto, N. Katakami, T.-A. Matsuoka, and I. Shimomura, “Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy,” Endocrine Journal, vol. 59, no. 12, pp. 1131–1136, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Katsuno, H. Ikeda, K. Ida, J.-I. Miyagawa, and M. Namba, “Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus,” Endocrine Journal, vol. 60, no. 6, pp. 733–742, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Kadowaki, N. Tajima, M. Odawara et al., “Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy,” Diabetology International, vol. 4, pp. 160–172, 2013. View at Google Scholar
  10. Y. Mori, Y. Taniguchi, S. Miyazaki, J. Yokoyama, and K. Utsunomiya, “Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy,” Diabetes Technology and Therapeutics, vol. 15, no. 3, pp. 237–240, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Seino, K. Nanjo, N. Tajima et al., “Report of the Committee on the classification and diagnostic criteria of diabetes mellitus: the Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus,” Diabetology International, vol. 1, no. 1, pp. 2–20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. G. D. Molnar, W. F. Taylor, and M. M. Ho, “Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability,” Diabetologia, vol. 8, no. 5, pp. 342–348, 1972. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Bando, K. Ishikura, H. Kanehara et al., “Determinants of the HbA1c-lowering effect of sitagliptin when added to ongoing insulin therapy in Japanese patients with type 2 diabetes,” Diabetology International, vol. 4, pp. 251–256, 2013. View at Google Scholar
  14. B. Ahrén, M. Landin-Olsson, P.-A. Jansson, M. Svensson, D. Holmes, and A. Schweizer, “Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 5, pp. 2078–2084, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. “Executive summary: standards of medical care in diabetes–2014,” Diabetes Care, vol. 37, supplement 1, pp. S5–S13, 2014.